SOLS Solstice Advanced Materials (SOLS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Chemicals & allied products · CIK 0002064953
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
492
13F, latest reported quarter
Conversions, 180 days
20
Codes C/M, not in net · no price filed
What the filings say about SOLS
Congress, 1 year
0 bought · 3 sold
Latest: sale, 2026-08-11
Solstice Advanced Materials insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Solstice Advanced Materials Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
492 funds bought in last quarter
more than 97% of Pharma & Biotech
Revenue
+3.1% year over year
more than 50% of Pharma & Biotech
Margin
6.1% net margin
more than 77% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
3.1% of the float short (float per yahoo 2026-10-27) · 2.6 days to cover · settled 2026-10-15
below 59% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SOLS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+31.5%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SOLS: institutional holders (13F)
13F holdings, latest reported quarter
15,931,864 sh
$1.4B
7,942,655 sh
$703.7M
7,173,963 sh
$635.6M
5,063,616 sh
$448.6M
3,355,801 sh
$297.3M
Congress trades in SOLS
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-08-11 · disclosed 14 days later
$1,001 - $15,000
Sold 2026-08-05 · disclosed 27 days later
$1,001 - $15,000
Sold 2025-11-24 · disclosed 12 days later
$1,001 - $15,000
Exchanged 2025-10-30 · disclosed 37 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SOLS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SOLS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P Spin-Off ETF
$10.4M position · as of 2026-07-31
4.6%
VIP Materials Portfolio
$2.7M position · as of 2026-06-30
3.2%
Select Materials Portfolio
$24.2M position · as of 2026-05-31
2.9%
Select Chemicals Portfolio
$11.9M position · as of 2026-05-31
2.7%
Range Nuclear Renaissance Index ETF
$24.0M position · as of 2026-05-31
2.7%
F/m Large Cap Focused Fund
$2.6M position · as of 2026-05-31
2.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · David Sewell
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$8.0M
$6.4M
$3.1M
-0%
+6%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 492 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SOLS financials
Revenue growth
+3.1%
XBRL, annual
Net margin
6.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SOLS
| FY Dec 2025 | $3.9B |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | $1.1B |
| Mar 2026 | $991.0M |
| Dec 2025 | $987.0M |
| Sep 2025 | $969.0M |
| Jun 2025 | $1.0B |
| Mar 2025 | $897.0M |
| Dec 2024 | $913.0M |
| Sep 2024 | $907.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+5.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SOLS
| FY Dec 2025 | +6.1% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | +10.4% |
| Mar 2026 | +8.6% |
| Dec 2025 | +4.2% |
| Sep 2025 | -3.6% |
| Jun 2025 | +9.4% |
| Mar 2025 | +14.9% |
| Dec 2024 | +14.6% |
| Sep 2024 | +16.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$195.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SOLS
| FY Dec 2025 | $119.0M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | $124.0M |
| Mar 2026 | $124.0M |
| Dec 2025 | $78.0M |
| Sep 2025 | -$131.0M |
| Jun 2025 | $74.0M |
| Mar 2025 | $98.0M |
| Dec 2024 | $180.0M |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
1.24x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity SOLS
| FY Dec 2025 | 1.40x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | n/a |
| Jun 2026 | 1.24x |
| Mar 2026 | 1.33x |
| Dec 2025 | 1.40x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.31x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt SOLS
| FY Dec 2025 | 0.23x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | 0.31x |
| Mar 2026 | 0.25x |
| Dec 2025 | 0.23x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+8.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SOLS
| FY Dec 2025 | +10.2% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | +8.3% |
| Mar 2026 | +8.0% |
| Dec 2025 | +10.2% |
| Sep 2025 | +10.2% |
| Jun 2025 | +15.6% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+3.5%
TTM net income over ending balance 2026-06-30
Return on assets SOLS
| FY Dec 2025 | +4.4% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | +3.5% |
| Mar 2026 | +3.3% |
| Dec 2025 | +4.4% |
| Sep 2025 | +6.3% |
| Jun 2025 | +10.3% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital SOLS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed SOLS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing SOLS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.8B
market value at close 2026-10-26 on 2026-07-23 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value SOLS
| FY Dec 2025 | $9.1B |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | $15.3B |
| Mar 2026 | $13.4B |
| Dec 2025 | $9.1B |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield SOLS
| FY Dec 2025 | +1.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | +1.4% |
| Mar 2026 | +1.2% |
| Dec 2025 | +1.5% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing SOLS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | |
|---|---|---|---|
| Revenue | $3.9B | $3.8B | $3.6B |
| Net income | $237.0M | $594.0M | $621.0M |
| EPS (diluted) | 1.49 | 3.74 | 3.91 |
| Operating cash flow | $455.0M | $842.0M | $760.0M |
| Cash | $534.0M | $661.0M | n/a |
| Long-term debt | $2.0B | $0 | n/a |
| Dividends paid | $1.5B | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
SOLS Stock Sonar score 5/7 axes
Find similar shapesCompareSOLS ranks highest on profitability (84th percentile) and risk and compliance (66th), and lowest on financial health (49th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SOLS filings, in plain words
Have members of Congress traded SOLS?
Yes. In the year to 2026-10-28, 0 House members disclosed buying SOLS and 3 House members disclosed selling it; the latest on record is a sale by Kelly Louise Morrison dated 2026-08-11.
Read the full summary
In the year to 2026-10-28, 0 members of Congress disclosed buying SOLS and 3 members disclosed selling it; the latest on record is a sale by Kelly Louise Morrison dated 2026-08-11. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
